Backed by FDA approval and a developed hospital system, the US is peramivir’s largest and most established market. The drug targets flu patients who are vomiting, critically ill, or otherwise unable to take oral therapy. Annual sales hinge on seasonal outbreaks and government stockpile purchases. Wider adoption is held back by the low price of oseltamivir and the ease of oral...